Skip to content


  • Poster presentation
  • Open Access

Recent advances in adoptive cancer immunotherapy in china

  • 1
Journal for ImmunoTherapy of Cancer20153 (Suppl 2) :P64

  • Published:


  • Advanced Gastric Cancer
  • Pancreatic Adenocarcinoma
  • Cancer Immunotherapy
  • Proliferation Ability
  • Uniform Criterion


Cytokine-induced killer (CIK) cells have been extensively used in treatment of cancer patients in China. Clinical trials demonstrated that there were markedly decreased tumor nodules in size in a patient with advanced pancreatic adenocarcinoma following four cycles of CIK cell infusion and thus the patient had a longer progression-free survival. Moreover, immunotherapy with CIK cells in combination with chemotherapy had more potential benefits including longer progression-free survival and overall survival in patients with cancer such as advanced gastric cancer and non-small-cell lung cancer as compared with chemotherapy alone. In addition, dendritic cell (DC)-CIK cells have increased proliferation ability, cytokine secretion and anti-tumor activity as compared with CIK cells alone.


A clinical trial showed that immunotherapy with tumor lysate-pulsed DC-CIK cells could significantly increase overall survival rates than no treatment control in renal cancer carcinoma patients. Thus, nowadays, DC-CIK cells have also been extensively used in treatment of cancer patients in China although the efficacy and mechanisms of adoptive cell transfer therapy with DC-CIK cells remains to be determined. In one word, the accumulation of basic researches and clinical studies related to cancer immunotherapy with CIK and DC-CIK cells has confirmed their safety and feasibility in treating malignant diseases. However, at present, there are still no uniform criteria or large-scale preparations of CIK and DC-CIK cells and the overall clinical response is difficult to evaluate due to lack of practical and appropriate criteria.


Large-scale, controlled, grouped, and multi-center clinical trials on CIK and DC-CIK cell-based immunotherapy should be conducted in the near future.



Supported by “Taishan Scholar” special fund from Shandong Government, China.

Authors’ Affiliations

Ludong University, Lexington, SC, USA